Vivoo is a wellness technology company that enhances access to personal health insights through at-home urine analysis kits and data tracking via mobile app.
Type: Impact Investment
Region: Global, Turkey
Sector: Access to Healthcare
Approval year: 2025
Healthcare & Awareness; Access to Primary and Preventive Healthcare
As part of Meem Foundation’s impact investment strategy, this co-investment alongside Mindshift Capital’s SPV supports the growth of a women-led health technology company that provides greater access to wellness testing. Vivoo enables individuals to monitor key health markers, promoting early awareness and preventive care. This investment aligns with Meem Foundation’s mission to expand access to women’s healthcare and advance sustainability through mission-aligned impact investing.
Headquartered in Turkey, Vivoo is founded by Miray Tayfun, Gozde Buyukacaroglu, and George Radman. Through Vivoo, users are able to capture significant personal health data and recieve personalized advice, product recommendations, and lifestyle advice (related to age, BMI, diet, chronic diseases, lifestyle).
Vivoo offers at-home urine testing kits that measure nine wellness indicators, including hydration, magnesium, calcium, pH, and urinary tract health. The tests sync with an intuitive mobile app that tracks users’ results and provides personalized wellness insights. They additionally offer ovulation and pregnancy test kits, fertility tests and vaginal Ph tests.
Through this investment, Meem Foundation supports a scalable, female-founded enterprise that is expanding preventative healthcare access worldwide. Proceeds from this investment will be reinvested into the Foundation’s philanthropic work towards a sustainable model of impact and innovation in women’s wellness.
